Cleo Diagnostics (ASX: COV) — Company Overview, News & Financial Data
Cleo Diagnostics is a medical diagnostics company developing novel blood tests for the early detection and triage of ovarian cancer.
Cleo Diagnostics
Cleo Diagnostics is a medical diagnostics company developing novel blood tests for the early detection and triage of ovarian cancer. The company's technology platform utilizes specific novel biomarkers to differentiate benign conditions from malignant ovarian tumors prior to surgical intervention. Cleo Diagnostics focuses on commercializing a pre-surgical triage test, a recurring monitoring test, and a high-risk screening test aimed at improving clinical outcomes for women. The company conducts clinical trial programs across the United States and Australia while partnering with international biotechnology firms for commercial assay manufacturing.
Snapshot
Operations
Products and/or services of Cleo Diagnostics
- Pre-Surgical Triage Test: Diagnostic blood assay designed to differentiate between benign and malignant ovarian masses in surgical candidates prior to operation, supporting optimal clinical referral pathways and surgical planning before invasive procedures.
- Cancer Recurrence Monitoring Test: Post-treatment blood testing assay intended to track ovarian cancer recurrence in diagnosed patients, providing longitudinal biomarker monitoring to evaluate therapeutic response and detect disease relapse standard protocols.
- Asymptomatic High-Risk Screening Test: Early detection blood screening assay targeted at women with elevated risk profiles or genetic predispositions, focused on identifying early stage ovarian malignancies prior to symptom manifestation across healthcare settings.
- Analytical and Clinical Validation Programs: Formal validation trials and laboratory evaluations utilizing commercial-grade test kits to verify analytical performance, repeatability, and clinical diagnostic accuracy in support of regulatory submissions.
- Pivotal Clinical Trial Operations: Multicenter clinical trial infrastructure operating across trial sites in the United States, gathering prospective blood samples from over five hundred patients to validate diagnostic test sensitivity and specificity.
- Contract Manufacturing and Commercial Supply: Strategic manufacturing operations with third-party biotechnology partners to produce standardized enzyme-linked assay kits, reagents, and diagnostic components for clinical trial supply and commercial distribution.
Cleo Diagnostics executive team
- Richard AllmanMD, CEO & Executive Director
- Andrew N. StephensChief Scientific Officer & Executive Director
- Thomas William JoblingLead Medical Advisor & Independent Non-Executive Director
- Nathan HodgsonHead of Operations
- Dayna LoucaHead of Corporate Development
- Pauline M. MoffattCompany Secretary
Latest news about Cleo Diagnostics
Recent announcements
What Cleo Diagnostics (COV) has told the market, newest first.
- CLEO Commences Analytical Validation Ahead of FDA SubmissionPrice sensitive
Key financials
Reported results for Cleo Diagnostics, in AUD.
- Market cap
- 39.9M
- Revenue (TTM)
- 1.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -7.9M | -5.9M | |
| 1.2M | -3.9M | -4M | |
| 600.2K | -3.6M | -3.8M | |
| 110.1K | -1.6M | -1.7M |